PROCEPT BioRobotics Corporation (NASDAQ: PRCT) saw a moderate increase in its share price today, reflecting investor interest in its specialized medical device offerings. The company’s market position in surgical robotics for urology continues to attract attention among healthcare investors.
Company Overview
PROCEPT BioRobotics Corporation is a surgical robotics company headquartered in Redwood City, California. Incorporated in 2007, the firm has developed the AquaBeam Robotic System, an image-guided tool used in minimally invasive urologic surgery, particularly for treating benign prostatic hyperplasia (BPH). The company also markets Aquablation therapy, offering a unique treatment option for males with lower urinary tract symptoms due to BPH. As of year-end 2021, PROCEPT held an installed base of 130 AquaBeam systems globally, with 78 located in the United States.
The company’s commitment to innovation in medical devices places it firmly in the healthcare sector, where precision, safety, and clinical outcomes are crucial.
Stock Performance
The latest stock price for PRCT stands at USD 34.8399, representing a change of 0.2299 or approximately 0.66% today. This modest gain reflects relatively stable trading conditions following broader market trends. The company’s 52-week range is between USD 33.83 and USD 103.81, indicating historical volatility and potential for variability in investor returns. PRCT does not currently pay a dividend, focusing resources on growth and development rather than shareholder payouts.
Current trading volume reached 640,159 shares, which is below its average volume of 1,175,185 shares, suggesting a quieter trading day. For short-term traders, volume shifts can signal changes in market sentiment, while long-term investors often view steady price ranges as a sign of stability.
Market Position and Sector
Operating in the medical devices industry, PROCEPT BioRobotics addresses a specialized segment within urology, balancing technology innovation with patient care requirements. The healthcare sector continues to evolve with enhanced surgical technologies, and companies like PROCEPT occupy important niches where they face limited direct competition but must maintain regulatory compliance and product efficacy.
Market capitalization currently sits at USD 1.938 billion, situating the company within the mid-cap category. Mid-cap firms often carry both growth potential and innovation capacity while being more established than small caps.
Governance and Leadership
Under the leadership of CEO Reza Zadno, PROCEPT BioRobotics emphasizes research and development with a clear focus on scalable production and global expansion. Leadership in medical technology companies requires balancing regulatory demands with market-driven innovation, and Zadno’s tenure has seen expansion of the AquaBeam system install base.
The company employs 756 full-time staff, reflecting a moderate organizational size for its industry. This workforce allows for agility and dedicated focus on advanced product development.
Key Financial Data
- Share Price: USD 34.8399
- Market Capitalization: USD 1,938,350,621
- Dividend: None declared
- 52-Week Range: USD 33.83 – USD 103.81
- Daily Change: +0.2299 (+0.66426%)
- Volume: 640,159
- Average Volume: 1,175,185
These indicators provide a snapshot of current performance and market positioning. Price changes inform valuations, while market cap gives context to company scale. Volume trends can signal investor activity shifts. The absence of dividends means all earnings are reinvested into company growth.
FAQ
- Does PROCEPT BioRobotics pay dividends?
No. The company currently reinvests earnings into growth and development. - Where is the stock traded?
Shares trade on the NASDAQ Global Market under ticker PRCT. - What is the ISIN and CUSIP?
ISIN: US74276L1052, CUSIP: 74276L105. - How many employees does the company have?
PROCEPT BioRobotics has 756 full-time employees. - What is the core product?
The AquaBeam Robotic System for minimally invasive urologic surgery.
Conclusion
PROCEPT BioRobotics continues to trade steadily, with a modest upward movement today. For investors, the company’s mid-cap status, specialized product line, and strong leadership suggest potential for growth balanced with sector-specific risks. Monitoring market performance, industry trends, and revenue streams will remain essential for assessing long-term value.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research before making investment decisions.
Official Source
For full information about the company, see the link below.